文献速递外周动脉疾病

外周动脉疾病患者强化降脂的成本效益分析

The cost-effectiveness of intensive low-density lipoprotein cholesterol lowering in people with peripheral artery disease.
PubMed 文献 · J Vasc Surg · 2020-09-03

该研究前瞻性纳入澳大利亚三所医院的783例外周动脉疾病患者(间歇性跛行582例,慢性肢体威胁性缺血201例),随访中位2.2年,基于随机试验的相对风险降低估算PCSK9抑制剂的绝对风险降低和成本效益。结果显示,在CLTI患者中强化降脂预估可降低MACE绝对风险6.1%(NNT=16)和MALE绝对风险13.7%(NNT=7),IC患者分别为3.2%(NNT=32)和5.3%(NNT=19);10年增量成本效益比在IC和CLTI患者中分别为55,270美元和32,800美元。结论提示PCSK9抑制剂在CLTI患者中可能具有成本效益。

要点

  • CLTI患者强化降脂预估MACE绝对风险降低6.1%,NNT=16。
  • CLTI患者MALE绝对风险降低13.7%,NNT=7。
  • PCSK9抑制剂在CLTI患者中可能具有成本效益。

核心结论

  • 在CLTI患者中,使用PCSK9抑制剂强化降脂可能具有成本效益。

研究设计与样本

  • 前瞻性队列研究,纳入澳大利亚三所医院的783例外周动脉疾病患者,其中间歇性跛行582例,慢性肢体威胁性缺血201例。
  • 随访中位2.2年(四分位距0.3-5.7年),测量基线血清LDL-C并记录MACE和MALE发生。
  • 基于已发表随机试验的相对风险降低,估算PCSK9抑制剂的绝对风险降低、NNT和增量成本效益比。

主要发现

  • CLTI患者强化降脂预估MACE绝对风险降低6.1%(95%CI 2.0-9.3;NNT=16),MALE绝对风险降低13.7%(95%CI 4.3-21.5;NNT=7)。
  • IC患者预估MACE绝对风险降低3.2%(95%CI 1.1-4.8;NNT=32),MALE绝对风险降低5.3%(95%CI 1.7-8.3;NNT=19)。
  • 10年增量成本效益比在IC患者中为55,270美元,在CLTI患者中为32,800美元。

临床怎么用

  • 对于CLTI患者,可考虑使用PCSK9抑制剂强化降脂以降低MACE和MALE风险。
  • IC患者使用PCSK9抑制剂的成本效益较低,需个体化评估。

局限性

  • 研究基于已发表随机试验的相对风险降低进行估算,而非直接试验数据。
  • 样本来自澳大利亚三所医院,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: People with peripheral artery disease are at a high risk of major adverse cardiovascular events (MACE) and major adverse limb events (MALE). Randomized controlled trials suggest that intensive lowering of low-density lipoprotein cholesterol (LDL-C) with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors is an effective strategy to prevent these events. This study estimated the potential benefit and cost-effectiveness of administrating PCSK9 inhibitors to a cohort of participants with peripheral artery disease. METHODS: A total of 783 participants with intermittent claudication (IC; n = 582) or chronic limb-threatening ischemia (CLTI; n = 201) were prospectively recruited from three hospitals in Australia. Serum LDL-C was measured at recruitment, and the occurrence of MACE and MALE was recorded over a median (interquartile range) follow-up of 2.2 years (0.3-5.7 years). The potential benefit of administering a PCSK9 inhibitor was estimated by calculating the absolute risk reduction and numbers needed to treat (NNT) based on relative risk reductions reported in published randomized trials. The incremental cost-effectiveness ratio per quality-adjusted life year gained was estimated. RESULTS: Intensive LDL-C lowering was estimated to lead to an absolute risk reduction in MACE of 6.1% (95% confidence interval [CI], 2.0-9.3; NNT, 16) and MALE of 13.7% (95% CI, 4.3-21.5; NNT, 7) in people with CLTI compared with 3.2% (95% CI, 1.1-4.8; NNT, 32) and 5.3% (95% CI, 1.7-8.3; NNT, 19) in people with IC. The estimated incremental cost-effectiveness ratios over a 10-year period were $55,270 USD and $32,800 USD for participants with IC and CLTI, respectively. CONCLUSIONS: This analysis suggests that treatment with a PCSK9 inhibitor is likely to be cost-effective in people with CLTI.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Nastasi DR, Moxon JV, Norman R, et al. The cost-effectiveness of intensive low-density lipoprotein cholesterol lowering in people with peripheral artery disease. J Vasc Surg. 2020. PMID: 32891803. doi:10.1016/j.jvs.2020.08.129

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。